How to select the optimal treatment for first line metastatic colorectal cancer

Table 4 Efficacy and tolerability of three to four drug first line regimen

Regimen	Efficacy				Tolerability
	PFS		OS		Grade 3/4 AE	SAE	Fatal AEs
	RAS wt	RAS mut	RAS wt	RAS mut
FOLFOX + panitumumab[25]	10.1	7.31	25.8	15.51	84%	40%	5%
FOLFIRI + cetuximab[4,62]	10.59.9 (KRAS exon 2)	NR1	33.123.5 (KRAS exon 2)	NR1	71%-79%	26%	NR
FOLFOX/XELOX + bevacizumab[56]	9.4		21.3		80%	NR	2%
FOLFIRI + bevacizumab[7,62]	10.4	NR	25.9	NR	NR	20%	3.5%
	9.7		25.8
FOLFOXIRI + bevacizumab[7]	12.1		31.0		NR	20%	2.8%

¹These fields only informative (epidermal growth factor receptor antibodies not licensed for RAS mutated tumours). Combination chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX), or irinotecan (FOLFIRI) or both (FOLFOXIRI), or capecitabine and oxaliplatin (XELOX). PFS: Progression free survival; OS: Overall survival; AE: Adverse events; SAE: Severe adverse events; NR: Not reported.